|
| Network Meta-analysis of oral Chinese patent medicine in the treatment of type 2 diabetic osteoporosis |
| Hits 212 Download times 139 Received:November 22, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.03.12 |
| Key Words
diabetic osteoporosis;type 2 diabetes mellitus;osteoporosis;Chinese patent medicine;network Meta-analysis |
| Author Name | Affiliation | E-mail | | YAN Zheng | Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
The Third Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China | | | MA Jia | The Third Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China | | | CUI Yinzhe | The Third Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China | | | XU Bo | The Second Department of Spine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China | | | DAI Junze | The Second Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China | | | ZHANG Boyu | The Third Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China | | | ZHANG Xuming | Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China | 992009986@qq.com;谢雁鸣，ktzu2018@163.com | | XIE Yanming | Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China | ktzu2018@163.com |
|
| Abstract
|
| [Objective] To evaluate the clinical efficacy and safety of different proprietary Chinese medicines in the treatment of T2DOP by network Meta-analysis. [Methods] Eight Chinese and English databases, including CNKI, VIP, PubMed, Cochrane Library and so on, were searched by computer until August 2023 to search for randomized controlled trials related to T2DOP. Bias risk assessment tool Cochrane was used to assess the bias risk included in the study, and R language was used to complete network Meta-analysis of the studies that met the quality standards. [Results] The 27 RCTs were eventually included, including 6 proprietary Chinese medicines and 2 930 patients, Chinese patent medicine combined with conventional treatment is superior to conventional treatment. The total effective rate of Tangmaikang Granule combined with CT is relatively better[OR=1.93, 95%CI(1.22, 2.75)]. Jintiange Capsule combined with CT has better effect on improving lumbar vertebrae bone density, femoral neck bone density and osteocalcin[MD=0.10, 95%CI(0.08, 0.14); MD=0.11, 95%CI(0.06, 0.16); MD=2.58, 95%CI(1.82, 3.37)]. Liuwei Dihuang Pill combined with CT has a better effect on reducing fasting blood glucose and glycosylated hemoglobin after treatment[MD=-1.53,95%CI(-2.34, -0.77);MD=-1.00,95%CI(-1.64, -0.37)]. In terms of safety, no serious adverse reactions occurred in all treatments, and there were few literatures included for quantitative analysis. [Conclusion] Tangmaikang Granule can significantly improve the clinical symptoms of T2DOP patients. Jintiange Capsule has obvious effect on bone mineral density in T2DOP patients, and Liuwei Dihuang Pill has more obvious effect on hypoglycemic effect. Limited by the quality of the included studies, the conclusions still need to be further verified. |
|
|
|
|
|
|
|
